Document:

Prepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document
 

Exhibit 10.17

Confidential treatment requested  

  
      DEVELOPMENT AND LICENSE AGREEMENT         

  GENENTECH, INC. AND SEATTLE GENETICS, INC.         

    This Development and License Agreement (this "Agreement") is made effective as of June 30, 1999 (the
"Effective Date") by and between Genentech, Inc. ("GNE"), a Delaware corporation with its
principal office at 1 DNA Way, South San Francisco, California 94080 and Seattle Genetics, Inc. ("SG"), a Delaware corporation with its principal
office at 22215 26th Avenue SE, Bothell, Washington 98021, each on behalf of itself and its Affiliates. GNE and SG are sometimes referred to herein individually as a
"Party" and collectively as the "Parties," and references to
"GNE" and "SG" shall include their respective Affiliates. 

  Recitals         

    WHEREAS, SG has begun development of antibodies binding the CD40 antigen, as well as fragments, conjugates and immunotoxins thereof (the
"Antibodies," as defined below) and owns or controls certain technology, including know-how and intellectual property, related thereto. 

    WHEREAS,
GNE and SG wish to continue development in a collaborative fashion and wish for GNE to commercialize the Antibodies so that the resources and expertise of each is put to good
use. 

    WHEREAS,
on the terms and subject to the conditions set forth herein, SG wishes to grant to GNE, and GNE wishes to receive, the rights set forth herein, including a license under SG's
technology and/or intellectual property rights to permit GNE to participate in the collaborative development, and to commercialize, market and promote the Antibodies. 

    NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, GNE and SG agree as follows: 

  Article I
       Definitions         

    1.1  "Affiliate" of a Party means any corporation or other business entity that, directly or indirectly,
through one or more intermediaries, controls, is controlled by, or is under common control with a Party. As used herein, the term "control" will mean the direct or indirect ownership of fifty percent
(50%) or more of the stock having the right to vote for directors thereof or the ability to otherwise control the management thereof. 

    1.2  "Agreement" means this Development and License Agreement, including any exhibits, schedules or other
attachments hereto and incorporated herein, as any of the foregoing may be validly amended from time to time. In the event of any inconsistency between the terms of this Agreement and the terms of any
exhibits, schedules or other attachments incorporated herein, the terms of this Agreement shall govern unless the Parties otherwise expressly agree in writing. 

    1.3  "Antibody" or "Antibodies" means any and all
anti-CD40 antibodies owned or controlled by SG, and shall include, without limitation, variants (including, without limitation, humanized versions) or fragments (including, without
limitation, single-chain versions) of such anti-CD40 antibodies, as well as conjugates of radionuclides, toxins or other compounds conjugated with such anti-CD40 antibodies or
fragments or variants thereof, as well as the DNA encoding any of the above. "Antibodies" shall include, without limitation, [*] (SGN14). "Antibodies" shall also include single
chain portions of SGN 11 and SGN 12 which may be used to create new toxin fusion constructs for the treatment of 

[*]   Confidential treatment requested 

1

cancer. Other forms of SGN 11 and SGN 12 shall be included in the term "Antibodies" only in the event that GNE exercises its opt-in right in accordance with the terms set
forth in Section 5.5. 

    1.4  "Anti-CD40 Patents" means any and all present or future patents, patent applications and
any patents issuing therefrom, in each case throughout the Territory, together with any extensions, registrations, confirmations, reissues, continuations, divisions, continuations-inpart,
re-examinations, substitutions or renewals thereof, to the extent they contain claims covering the manufacture, use or sale of a Licensed Product in the Field. 

    1.5  "BLA" means a biologics license application (as that term is used in Title 21 of the United States
Code of Federal Regulations) filed with the FDA seeking Regulatory Approval to market and sell any Licensed Product in the United States for a particular indication. 

    1.6  "BLA/NDA-Enabling Clinical Trial" means, as to a specific Licensed Product, a controlled
and lawful study in humans of the efficacy and safety of such Licensed Product, which is prospectively designed to demonstrate statistically whether such Licensed Product is effective and safe for use
in a particular indication in a manner sufficient to file a BLA or NDA to obtain regulatory approval to market and sell that Licensed Product in the United States for the indication being
investigated by the study. 

    1.7  "BMS Agreement" means the License Agreement between Bristol-Myers Squibb Company ("BMS") and SG
dated as of March 30, 1998. 

    1.8  "BMS Field" means the treatment and diagnosis of cancer in humans. 

    1.9  "BMS Patents" means the patents licensed to SG under the BMS Agreement that are identified in
Exhibit A. To the extent GNE exercises its opt-in rights for SGN 11 and SGN 12 pursuant to Section 5.5, Exhibit A will be amended to add any applicable
Anti-CD40 Patents. 

    1.10  "BMS Technology" means the BMS Patents and related know-how. 

    1.11  [*] 

    1.12  [*] 

    1.13  "Commercial Introduction" means, on a country-by-country basis in the
Territory, the date of first commercial sale (other than for purposes of obtaining regulatory approval) of a Licensed Product by GNE, its Affiliates or any sublicensee in such country. 

    1.14  "Commercially reasonable and diligent efforts" has the meaning set forth in Section 3.3. 

    1.15  "Combination Product" means any Licensed Product that contains, in addition to any Antibody, one or
more other ingredient that has biologic activity as a therapeutic agent when presented alone. 

    1.16  "Competing Product" has the meaning set forth in Section 5.7. 

    1.17  "Confidential Information" has the meaning set forth in Section 8.1 

    1.18  "Control" means possession of the ability to grant access to or a license or sublicense as provided
for herein without violating the terms of any agreement or other arrangement with any third party. 

    1.19  "Development Plan" means any plan for development work relating to Licensed Products, and any
modifications to any such work plan, as may be created under Article 2 from time to time during the Term of this Agreement. Any Development Plan(s) created hereunder, or any modifications to
any Development Plan(s), shall be incorporated into this Agreement effective automatically upon valid adoption of such Development Plan(s). 

2

    1.20  "Development Period" means the period of time from the Effective Date to the first filing of an IND
for a Licensed Product. 

    1.21  "Drug Approval Application" means an application for Regulatory Approval required for commercial
sale or use of a Licensed Product as a drug or biologic in the Field in a regulatory jurisdiction. 

    1.22  "Effective Date" has the meaning set forth in the introductory paragraph. 

    1.23  "FDA" means the United States Food and Drug Administration and any successor agency or authority
thereto. 

    1.24  "Field" means any human use. 

    1.25  "Foreign Regulatory Authority" means any applicable regulatory agency, department, bureau or other
governmental entity or authority of any country or regulatory jurisdiction in the Territory (other than the FDA in the United States), having responsibility in such country or regulatory jurisdiction
for any Regulatory Approvals of any kind necessary for the development, pre-clinical and/or human clinical testing, manufacture, supply, marketing and/or sale of Licensed Products in such
country or other regulatory jurisdiction. 

    1.26  "GNE" means Genentech, Inc., a Delaware corporation, and its successors and permitted
assigns under this Agreement. 

    1.27  "GNE Know-how" means any and all materials, data, results, formulae, designs,
specifications, methods, processes, techniques, ideas, discoveries, technical information, process information, clinical information, regulatory information and submissions, and any other information,
developed by GNE in the course of its performance of this Agreement and as to which GNE has the right to transfer or grant licenses or sublicenses, to the extent that any of the foregoing pertains to
and is necessary for SG to develop and commercialize an Antibody, including data and cell lines (and pertinent information related thereto) pertaining to the Antibodies. "GNE Know-how"
shall not include any of the foregoing which is generally ascertainable from publicly available information or that was known to SG prior to
disclosure to SG (as evidenced by prior competent proof) or which SG obtained independently or in collaboration with another partner and not in violation of any obligation of confidentiality owed to
SG or any third party, nor shall it include manufacturing or process information, techniques, data or SOP's unless GNE decides to provide such information. 

    1.28  "GNE Patents" means any and all Anti-CD40 Patents that are owned by GNE that are based
upon inventions conceived or reduced to practice by GNE employees in the course of performing GNE's development obligations under this Agreement, including GNE's interest in any anti-CD40
Patents owned jointly by the Parties as provided hereunder. "GNE Patents" shall not include general patents covering manufacturing or process inventions, nor any patents arising from work performed
not in relation to this Agreement. 

    1.29  "Improvement" means any enhancement(s), improvement(s) or modification(s), whether or not
patentable, to a Licensed Product or involving its use or manufacture, that either (a) is or are created or identified by either Party in connection with any development work or
commercialization efforts under this Agreement, or (b) are feature(s), technology(ies) or component change(s) created by GNE or SG independently of any such development or commercialization
efforts under this Agreement. By way of clarification, Improvements include any improvement, enhancement or modification which does not require pivotal human clinical trials for Regulatory Approval. 

    1.30  "IND" means an Investigational New Drug Application filed or to be filed with the FDA with regard
to a Licensed Product. 

    1.31  "JOC" has the meaning set forth in Section 2.1(a). 

3

    1.32  "Joint Patents" has the meaning set forth in Section 7.1. 

    1.33  "Licensed Product" means any product containing an Antibody or Antibodies or any formulation
thereof, including, without limitation, any lyophilized liquid, sustained release or aerosolized formulation containing an Antibody or Antibodies. "Licensed Product" shall also include Combination
Products and New Products. 

    1.34  "NDA" means a new drug application (as that term is used in Title 21 of the United States Code of
Federal Regulations) filed with the FDA seeking Regulatory Approval to market and sell any Licensed Product in the United States for a particular indication. 

    1.35  "New Product" shall mean a new Licensed Product based upon a different Antibody than an existing
Licensed Product, or any second or later generation product containing an Antibody(ies), which later generation product is so significant a modification of a Licensed Product that it requires pivotal
human trials for Regulatory Approval. Notwithstanding the foregoing, modifications to the formulation or manufacturing of an existing Licensed Product, such as development of liquid, sustained release
or aerosolized formulations of an existing Licensed Product, shall not constitute a "New Product" but rather shall be deemed an original Licensed Product. In contrast, a new drug or immunotoxin
conjugate or fusion of the Antibody in an existing Licensed Product, or fragments thereof, shall constitute a New Product. 

    1.36  "Net Sales" means, as to each calendar quarter, the gross invoiced sales prices charged for all
Licensed Products sold by or for GNE, its Affiliates and sublicensees to independent third parties during such quarter, after deduction (if not already deducted in the amount invoiced) of the
following items paid by GNE, its Affiliates and sublicensees during such calendar quarter with respect to sales of Licensed Products regardless of the calendar quarter in which such sales were made,
provided and to the extent that such items are incurred or allowed and do not exceed reasonable and customary amounts in the market in which such sales occurred: 

    (a) trade
and quantity discounts or rebates actually taken and allowed, including discounts or rebates to governmental or managed care organizations; 

    (b) credits
or allowances given or made for rejection or return of previously sold Licensed Products; 

    (c) any
tax, tariff, duty or government charge (including any tax such as a value added or similar tax or government charge other than an income tax) levied on the
sale, transportation or delivery of a Licensed Product and borne by the seller thereof without reimbursement from any third party; 

    (d) any
charges for freight from the seller, or for insurance, borne by the seller. 

    Notwithstanding
the foregoing, no deduction shall be made for bad debt expense. All of the foregoing deductions from the gross invoiced sales prices of Licensed Product shall be
determined in accordance with GAAP. In the event that GNE, its Affiliates or sublicensees make any adjustments to such deductions after the associated Net Sales have been reported pursuant to this
Agreement, the adjustments shall be reported and reconciled with the next report and payment of any royalties due. 

    1.37  "Party" means GNE or SG, and, when used in the plural, shall mean both of them. 

    1.38  "Phase II Clinical Trial" means, as to a specific product, a controlled and lawful study in humans
of the safety, dose ranging and efficacy of such Licensed Product, which is prospectively designed to generate sufficient data (if successful) to commence a BLA/NDA Enabling Clinical Trial (or foreign
equivalent) of such product. 

    1.39  "Previous Agreement" means that certain Material Transfer and Heads of Agreement between the
Parties effective as of April 20, 1999. 

4

    1.40  "Regulatory Approval" means any and all approvals (including pricing and reimbursement approvals),
licenses, registrations or authorizations of any kind of the FDA or any Foreign Regulatory Authority necessary for the development, pre-clinical and/or human clinical testing, manufacture,
supply, marketing and sale of a Licensed Product in any country or other regulatory jurisdiction in the Territory. "Regulatory Approval" shall include, without limitation, any BLA, NDA or foreign
equivalent. 

    1.41  "SG" means Seattle Genetics, Inc., a Delaware corporation, and its successors and permitted
assigns under this Agreement. 

    1.42  "SG Inventions" has the meaning set forth in Section 7.5 

    1.43  "SG Know-how" means any and all materials, data, results, formulae, designs,
specifications, methods, processes, techniques, ideas, discoveries, technical information, process information, clinical information and any other information, whether or not any of the foregoing is
patentable, that are owned or controlled by SG solely or jointly as of the Effective Date or hereafter during the Term of this Agreement and as to which SG has the right to transfer or grant licenses
or sublicenses, to the extent that any of the foregoing relates to any SG Patent Rights or BMS Patents or is necessary or useful for the research, development, manufacture, use import, export or sale
of any Licensed Product or Improvement in the Field in the Territory. "SG Know-how" shall not include any of the foregoing which is generally ascertainable from publicly available
information or that was known to GNE prior to disclosure to GNE by SG (as evidenced by prior competent proof) or which GNE obtained independently or in collaboration with another partner and not in
violation of any obligation of confidentiality owed to SG or any third party. 

    1.44  "SG Patent Rights" means any and all patents and patent applications (including inventor's
certificates and utility models) throughout the Territory, including any substitutions, extensions, reissues, reexaminations, renewals, divisions, continuations and
continuation-in-parts of any of the foregoing, that are owned or controlled by SG (solely or jointly) as of the Effective Date or hereafter during the Term of this Agreement,
excluding the BMS Patents, and as to which SG has the right to grant licenses or sublicenses, to the extent that any of the foregoing is necessary or useful for the research, development, manufacture,
use, import, export or sale of any Licensed Product or Improvement in the Field in the Territory. The "SG Patent Rights" shall include, without limitation, the patents and patent applications listed
on Exhibit B attached hereto and incorporated hereby into this Agreement. SG shall use its best efforts to amend  Exhibit B by December 31 of
each year of the Term of this Agreement to include any SG Patent Rights that have arisen in the period since
the Effective Date or since the last amendment to Exhibit B, provided, however, that if SG does not so amend  Exhibit B by December 31 of any
year during the Term of this Agreement, SG shall so amend  Exhibit B within thirty (30) days after receipt of any written request from GNE. 

    1.45  "SGN 11&12" means [*], respectively. 

    1.46  "SGN 18" means [*]. 

    1.47  "T7 Technology" means the technology described in the certain License Agreement dated as of
January 1, 1998, between SG and Brookhaven Science Associates LLC (the "T7 License"), a copy of which (redacted for financial terms only) has been provided to GNE. T7 Technology is a component
of SG Patent Rights and/or SG Know-how. 

    1.48  "Term" has the meaning set forth in Section 9.1. 

    1.49  "Territory" means the world. 

5

    1.50  "Valid Claim" means a claim in an unexpired patent within the SG Patent Rights that (a) has
not been revoked, held invalid, declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction, and that is unappealable or unappealed within the time allowed
for appeal and (b) has not been rendered unenforceable through disclaims or otherwise and (c) is otherwise not subject to an interference claim. Notwithstanding the foregoing, if an
issued claim within the SG Patent Rights that is in existence within ten years of Commercial Introduction of the relevant Licensed Product in a country is the subject of an interference that is later
resolved in SG's favor, then such claim shall be considered a "Valid Claim" under this Agreement and (i) GNE shall promptly pay to SG back royalties that it would have owed under this Agreement
if such claim had not been subject to an interference, and (ii) GNE shall continue to pay royalties for the remaining life of such Valid Claim. 

  Article 2
       Management of Development         

    2.1  Joint Oversight Committee. 

    (a) GNE
shall have full responsibility for and control of pre-clinical and clinical development and commercialization of Licensed Products. Within thirty
(30) days of the Effective Date, the Parties will establish a Joint Oversight Committee (the "JOC") to review progress on the
pre-clinical portion of the product development contemplated by this Agreement. The goal of the JOC is to facilitate the exchange of information and the coordination between the Parties
relating to the development of Licensed Products. The JOC will be composed of two representatives of each Party, who shall be appointed (and may be replaced at any time) by such Party on written
notice to the other in accordance with this Agreement. Such representatives shall include individuals within the organization of each Party with expertise in biopharmaceutical drug development. Any
member of the JOC may
designate a substitute to attend and perform the functions of that member at any meeting of the JOC. The JOC will meet at least twice annually during the Development Period and at least once annually
following the Development Period but prior to commencement of a Phase III clinical trial, or at any other frequency agreed by the JOC. After commencement of a Phase III clinical trial, the JOC shall
meet when and if agreed to by the JOC. 

    (b) Without
limiting the foregoing, the JOC shall perform the following functions with regard to pre-clinical development of the Antibodies: 

     (i) be
responsible for allocating development duties among the Parties, for reviewing development plans, for exchanging information and facilitating cooperation and
coordination between the Parties, and for implementing all activities approved by the JOC or GNE, as the case may be; and 

    (ii) receiving
and reviewing the annual reports to be delivered by each party pursuant to Section 3.7 below. 

    2.2  Decision Making Responsibility. The Parties intend and agree that the development and
commercialization of Licensed Products in the Field in the Territory shall be GNE's responsibility, subject to the other terms of this Agreement. Without limiting the generality of the foregoing, GNE
shall be responsible for making and have authority to make all decisions, and undertaking any actions necessary as a result of such decisions, regarding preclinical and clinical development plans,
selecting drug candidates and filing an IND. 

6

  Article 3
       Development         

    3.1  Development Responsibilities; Goals. 

    (a) Licensed Products. Subject to the other terms of this Agreement, and except as set forth below, GNE shall be solely
responsible for the conduct of all development, pre-clinical and human clinical testing, regulatory filings and Regulatory Approvals with respect to all Licensed Products in the Territory,
and all costs and expenses in connection therewith. Each Party shall perform its respective tasks and obligations in conducting all development work ascribed to it in the Development Plan with
commercially reasonable and diligent efforts, and each Party shall cooperate with and provide reasonable support to the other Party in such other Party's conduct of such development and
commercialization work as provided in the Development Plan. 

    (b) SGN 11&12 [*]. Unless and until GNE exercises its rights pursuant to Sections 5.5 and 5.6
below, SG shall be solely responsible, at its own expense, for the development of SGN 11& 12 [*]. 

    3.2  Initial Development Plan; Modifications. As soon as practicable after the Effective Date, the
Parties will create an initial Development Plan which will address the initial phases of development of Licensed Products; provided, however, that GNE
shall have final authority regarding the Development Plan, subject to Section 3.3 below. The long term goals of the Development Plan are: (a) the development (including clinical testing)
of the Licensed Product as needed to seek Regulatory Approval; (b) the acquisition of Regulatory Approval of the Licensed Product allowing the commercial promotion, marketing and sale of the
Licensed Product in the Territory for use in the Field; and (c) the development of capabilities to manufacture and supply Licensed Product for such development and commercialization. 

    3.3  Development Efforts. 

    (a) SG
and GNE each agree to use commercially reasonable and diligent efforts to collaborate to develop and bring a Licensed Product to market in the Field. The Parties
further agree to cooperate with the other in carrying out the Development Plan. As used in this Agreement, the term commercially reasonable and diligent efforts will mean those efforts consistent with
the exercise of prudent scientific and business judgment, as applied to other pharmaceutical products of similar potential and market size by the Party in question. 

    (b) GNE's Diligence. Without limiting the generality of the foregoing, GNE's due diligence obligations regarding the
development for the Antibodies shall include filing an IND with regard to an Antibody within [*] ([*]) years of the Effective Date. 

    (c) Remedies. (i) If GNE does not meet the diligence obligation set forth in subparagraph (a) above, then
SG may terminate this Agreement on six (6) months written notice, provided, however, that GNE has not cured such failure by the end of such six
(6) month notice period, and provided, further, that GNE shall not be considered in default of its obligations under subparagraph
(a) above for a period of one year following the end of such six month period if, as evidenced by documented records, it is making an active effort to find a sublicensee for its rights under
this Agreement on commercially reasonable terms. In the event the Agreement is terminated by SG under this Section 3.3(c)(i), or unilaterally by GNE under Section 9.2 after a filing by
GNE of an IND on a Licensed Product, then, upon request of SG, the Parties shall negotiate in good faith a commercially reasonable license to SG under the GNE Patents, GNE Know-how,
Improvements and Regulatory Approvals or submissions, at royalty rates to be determined by good faith negotiations of the parties at the time of such termination, taking into account factors
including, 

7

but not limited to, the financial investment by GNE during the term of the Agreement, the relative contributions of the Parties to the pre-clinical and clinical development of, and the
regulatory efforts relating to, the product or products subject to royalties, the degree of protection that the GNE Patents and GNE Know-how afford against unlicensed competition, the
potential market size for such product or products, and the then current "market rates" for royalties on licenses of similar scope for programs at a similar stage of development;  provided, however, that
in no event shall the rate of such royalties be less than the rates set forth in Section 6.4 below. 

    (ii) If
GNE does not meet the diligence obligation set forth in subparagraphs (b) above, then SG may terminate this Agreement on six (6) months written
notice, provided, however, that GNE has not cured such failure by the end of such six (6) month notice period. In the event the Agreement is terminated by SG under this
Section 3.3(c)(ii), or unilaterally by GNE under Section 9.2 prior to the filing by GNE of an IND on a Licensed Product, then, (A) upon request of SG, GNE shall grant a license to
SG to all GNE Patents, GNE Know-how, Improvements and Regulatory Approvals or submissions; and (B) SG shall owe GNE royalties as set forth in Section 6.4 below. 

    3.4  SG's Development Responsibilities. 

    (a) Transfer of Information. Consistent with its responsibility under the Development Plan, SG agrees to transfer to
GNE, at SG's cost, all SG Know-how, preclinical data, assays and associated materials, protocols, procedures and any other information in SG's possession or control, necessary or desirable
to continue pre-clinical or initiate clinical development of Antibodies. 

    (b) Assistance in Regulatory Filings. During the Term, SG shall assist GNE and any sublicensee in the preparation and
filing for any Regulatory Approval with respect to Licensed Products in the Territory, by delivering, at GNE's request and expense, all information in SG's possession (in a complete and accurate form)
necessary to complete and file any Regulatory Approval for a Licensed Product. 

    (c) Adverse Events. During the Term, SG shall report promptly to GNE and any sublicensee the occurrence of any adverse
events relating to any Licensed Product or component thereof as necessary to comply with the adverse event reporting regulations of the FDA (as provided in Title 21 of the Code of Federal
Regulations) and Foreign Regulatory Authorities. 

    3.5  GNE's Development Responsibilities. 

    (a) GNE
shall undertake its development obligations, as set forth in this Agreement. 

    (b) GNE
agrees to conduct all research pursuant to this Agreement in a good scientific manner, and in compliance in all material respects with the requirements of
applicable laws, rules and regulations, and other requirements of applicable good laboratory or clinical practices. 

    (c) GNE
shall maintain records, in sufficient detail and good scientific manner, which shall be complete and accurate and shall fully and properly reflect all work done
and results achieved in the performance of its development obligations under this Agreement (including data in the form required under applicable laws and regulations). 

    (d) Upon
request, GNE agrees to promptly provide SG with a copy of the NDA or NDA equivalent, Regulatory Approval letters and, upon specific request by SG, other
material correspondence to or from health authorities relating to material developments affecting the Product. 

    3.6  Drug Approval Applications. Consistent with the Development Plan, GNE shall be responsible for, and
will use commercially reasonable and diligent efforts in, filing Drug Approval 

8

Applications and seeking Regulatory Approvals for Licensed Products in the Territory. GNE shall own all regulatory submissions including all Drug Approval Applications for Licensed Products in the
Territory. 

    3.7  Development Costs. During the Development Period, each Party shall bear its own costs and expenses
associated with pre-clinical experiments or other activities assigned to it by the JOC. Notwithstanding the foregoing and notwithstanding the provisions of Section 2.1(a), the JOC
shall not have the authority to assign tasks or allocate developmental expenses to SG without the approval of SG's representative on the JOC. All costs associated with the development of Licensed
Products in the Territory other than those allocated to SG by the JOC, including costs of Phase I, Phase II and Phase III clinical Trials, shall be borne by GNE. 

    3.8  Updates; Publications. Each Party shall update the other regularly, including but not limited to
notice of commencement of any clinical trial, and in no event less frequently than yearly, by submitting an annual report to the JOC describing its progress and results under any Development Plan
hereunder and other efforts related to its anti-CD40 program, which updates and/or annual reports shall be considered Confidential Information of the disclosing Party under
Section 8. Any publications regarding the subject matter of this Agreement shall be subject to Section 8, and authorship of any such publications shall be determined by mutual agreement
of the Parties. 

    3.9  Materials; Disclaimer of Warranties; Responsibility. 

    (a) Each
Party shall use any biologic materials, supplies or devices provided to it by the other Party hereunder, and any derivatives or conjugates thereof (the
"Materials"), only for the purposes described in this Agreement. 

    (b) WITH
RESPECT TO THE SUPPLY OF MATERIALS HEREUNDER, EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, EACH PARTY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, REGARDING THE MATERIALS SUPPLIED BY SUCH PARTY HEREUNDER. 

    (c) Except
as provided in this Agreement to the contrary, each Party shall be solely responsible and liable for all activities undertaken by it using any Materials
provided to it by the other Party hereunder, except to the extent resulting from such providing Party's negligence or willful misconduct or the breach of any its representations, warranties or
covenants with respect thereto. 

  Article 4
       Commercialization in the Territory         

    4.1  Commercialization Efforts; Costs. GNE shall use its commercially reasonable and diligent efforts to
develop and commercialize each Licensed Product in each country in which Regulatory Approval is received. GNE shall have the sole responsibility for, and right to make all decisions regarding, all
commercialization activities, including without limitation sales, marketing and product launch activities and tactical execution of marketing and sales promotional programs in the Territory, and all
marketing and promotional materials related to Licensed Products shall be prepared by GNE. GNE shall bear all costs related to the commercialization of the Licensed Products in the Territory. SG
agrees that it will not knowingly take any action that could imperil Regulatory Approvals in any country in the Territory. 

9

  Article 5
       Licenses; Grants of Rights         

    5.1  Grant of Rights to GNE. 

    (a) SG Patent Rights and Know-how. Subject to the other terms of this Agreement, SG hereby grants to GNE an
exclusive license (even as to SG), with the right to sublicense, within the Territory to SG Know-how and SG Patent Rights, to research, develop, manufacture or have manufactured, use,
import, export, sell or offer for sale any and all Licensed Products, New Products and/or Improvements thereto within the Field in the Territory. In connection with the exclusive grant under this
Section 5.1(a), and subject to the other terms of this Agreement, SG shall provide to GNE and any sublicensee such
information and materials comprising the SG Know-how and the SG Patent Rights as it or they may reasonably request. 

    (b) BMS Patent Rights. Subject to the other terms of this Agreement, SG hereby grants to GNE an exclusive license (even
as to SG) within the Territory to the BMS Patent Rights, to research, develop, manufacture or have manufactured, use, import, export, sell or offer for sale any and all Licensed Products, New Products
and/or Improvements thereto for use in the BMS Field in the Territory. GNE's right to sublicense the BMS Patent Rights is limited solely to use with the Antibody and is subject to the prior approval
of SG and BMS. In connection with the exclusive grant under this Section 5.1(b), and subject to the other terms of this Agreement, SG shall provide to GNE and any approved sublicensee such
information and materials comprising the BMS Patent Rights as it or they may reasonably request. 

    (c) T7 Technology. GNE shall have the right, upon written notice to SG, to sublicense, at GNE's option, T7 Technology
from SG nonexclusively for use with Licensed Products for human cancer uses only in the Territory, on the same terms and conditions, including payments and royalties, applicable to SG as set forth in
the T7 License. 

    5.2  Retained Rights. Subject to the other terms of this Agreement, SG retains the right to use the SG
Know-how and practice the SG Patent Rights to perform its work under the Development Plan and otherwise support the development and commercialization of Licensed Products as provided in
this Agreement. In addition to the foregoing, and subject to the other terms of this Agreement, including, without limitation Sections 5.5 and 5.7, SG retains the right to develop (but not license to
a third party in conflict with the provisions of this Agreement) SGN 1 l&12, at its sole cost and expense. 

    5.3  Sublicenses. GNE shall have the right freely to grant sublicenses of its rights under this
Agreement, subject to any prior approval required by Section 5.1(b), to research, develop, manufacture, use, import, export and/or sell Licensed Products, provided,
however, that: (a) GNE guarantees the making of all payments due to SG by reason of Net Sales of any Licensed Products by any such sublicensee and its compliance with
all terms of this Agreement applicable to GNE (including, without limitation, all terms of this Agreement identified as applicable to a GNE sublicensee); and (b) any such sublicensee agrees in
writing (i) to keep books and records and permit SG to review the information concerning such books and records that GNE has in its possession in accordance with the terms of this Agreement and
(ii) to comply with all other terms of this Agreement applicable to GNE (including, without limitation, all terms of this Agreement identified as applicable to a GNE sublicensee). GNE shall
notify SG in writing of any such sublicensee. 

    5.4  New Products. The scope of this Agreement, including the license rights granted to GNE under
Section 5.1, encompasses the potential development of New Products. All New Products are subject to the terms and conditions of this Agreement, and any New Product chosen for development and
commercialization by GNE under the terms of this Agreement shall be considered a Licensed Product subject to the same royalties as any other Licensed Product under this Agreement. If any New 

10

Product is the first Licensed Product to reach any of the milestones set forth in Section 6.1(a)(ii)-(viii), such New Product shall trigger the payment of such milestone.
[*] 

    5.5  SGN 11&12. SG hereby grants GNE the right to elect to include SGN 11 and 12 specifically (other than
single chain portions thereof as set forth in Section 1.3, which are included in the grant of rights under Section 5.1) as Antibodies, and the patents related thereto as SG Patents and
BMS Patents, as applicable, for use in the BMS Field under this Agreement as follows (the "SGN 11/12 Option"): for a period of
[*] ([*]) years from the Effective Date, GNE shall have the right to exercise the SGN 11/12 Option; provided,
however, that if no [*] for SGN 11&12 agreed to by both GNE and SG shall have been successfully completed (i.e., it has proved its primary hypothesis)
within such [*] ([*]) year period, then the period to exercise the SGN 11/12 Option under this Agreement shall be extended until 90 days
following GNE's receipt of a final report of the results of such a [*]. If GNE elects to exercise the SGN 11/12 Option, GNE shall notify SG of such election in writing, and
within thirty (30) days of such notice shall make a payment to SG in the amount of [*] dollars ($[*]). From and after the receipt by SG of the
payment set forth above, both SGN 11&12 will be considered Antibodies under this Agreement, and all SG Patents and BMS Patents related to SGN 11 and SGN 12 shall be added to this Agreement, and
royalties and milestones applicable to its development and commercialization shall be determined in accordance with Section 6.1. If a Licensed Product incorporating SGN 11 and SGN 12 is the
first product to complete a milestone set forth in Section 6.1(a), then the applicable amount set forth in Section 6.1(a) will become due and payable to SG. [*]
Notwithstanding anything in this Agreement, SG shall not be obligated to initiate or continue a development program for SGN 11 or SGN 12. 

    5.6  [*] 

    (a) [*] 

    (b) [*] 

    5.7  [*] 

    5.8  Compliance with BMS Agreement. With respect to the BMS Technology, GNE hereby agrees to comply with
the covenants and conditions of the BMS Agreement set forth in Exhibit C hereto as if they were a party to the BMS Agreement. To the extent the
BMS Agreement is amended to include additional terms and conditions, the parties agree to amend Exhibit C to include such terms and conditions as
are relevant to the BMS Technology; provided, however, that SG shall not enter into any amendment to the BMS Agreement that would impair the rights of
GNE under this Agreement, without the prior written consent of GNE; and provided, further, that SG shall not enter into any amendment to the BMS
Agreement that imposes additional obligations on GNE, or may reduce the benefits to GNE of the BMS Agreement, without the prior written consent of GNE. 

  Article 6
       Milestones and Royalties; Equity Purchases         

    6.1  Milestones. 

    (a) Milestones for First Licensed Product. Subject to the other terms of this Agreement, and as consideration to SG for
the licenses and other rights granted to GNE under this Agreement, in addition to the $[*] paid by GNE to SG prior to execution of this Agreement, GNE shall pay to SG the
following milestone payments upon the first occurrence of each event set forth below with respect to the first Licensed Product to reach such stage. For purposes of clarification, each 

11

milestone in this Section 6.1(a) shall be payable only once, within thirty (30) days of when the first Licensed Product to reach such stage of development does reach such stage of
development; [*] 

	Milestone
 
	 	 
	 	Payment

	(i)	 	Execution of Agreement	 	$	[*]
	(ii)	 	Filing of IND by GNE	 	$	[*]
	(iii)	 	Commencement of first Phase III clinical trials in United States	 	$	[*]
	(iv)	 	FDA approval of Anti-CD40 Licensed Product for first indication	 	$	[*]
	(v)	 	First approval in EU	 	$	[*]
	(vi)	 	First approval in Japan	 	$	[*]
	(vii)	 	Total US sales first reach $[*] annually $[*]or $[*] in the aggregate	 	$	[*]
	(viii)	 	Total US sales first reach $[*]	 	$	[*]

    (b) [*]

    6.2  Royalties. Subject to the other terms of this Agreement, and as consideration to SG for the licenses
and other rights granted to GNE under this Agreement, commencing as to each country in the Territory on the date of Commercial Introduction of the first Licensed Product in such country, GNE shall
make royalty payments to SG with respect to Net Sales of each Licensed Product in such country by GNE and any sublicensee(s) (using the foreign currency exchange provisions of Section 4.6(b) to
calculate worldwide Net Sales in U.S. Dollars), as follows: 

    (a) Subject
to Section 6.2(b), for any Licensed Product containing a construct of the Antibody that SG prepares and provides to GNE, GNE shall pay a royalty of
[*] percent ([*]%) of Net Sales. 

    (b) For
any Licensed Product that has been humanized or substantially altered by GNE from SG's construct of the Antibodies (e.g., by affinity maturation, etc.), GNE
shall pay a royalty of [*] percent ([*]%) of Net Sales. 

    6.3  Third Party Royalties. On a country-by-country basis, the royalties
otherwise due and payable by GNE hereunder shall be reduced by an amount equal to [*] percent ([*]%) of the amounts GNE or any sublicensee must pay to
any third party with respect to the development, manufacture, import or export, use or sale of any Licensed Product; provided, however, that in no event
shall the royalty payments due and payable to SG be reduced by this Section 6.3 below [*] percent ([*]%) of Net Sales of such Licensed Product by
GNE and any sublicensee(s) in such country; and provided, further, that for so long as there is no other product in the market in such country that
interacts with the CD40 antigen and competes with the Licensed Product, the royalty payments due and payable to SG shall not be reduced by this Section 6.3 below [*]
percent ([*]%) of Net Sales of such Licensed Product by GNE and any sublicensee(s) in such country. If GNE believes in good faith that there is a competing product, it shall
give notice to SG of such conclusion and GNE's intention to offset royalties payable to SG pursuant to this Section 6.3 subject to a minimum royalty of [*] percent
([*]%). If SG disagrees with GNE's conclusion that there is a competing product, the dispute will be resolved in accordance with the provisions of Section 12.12. 

    6.4  Royalties payable by SG. In the event that SG terminates this Agreement pursuant to
Section 3.3(c)(ii), or GNE terminates this agreement pursuant to Section 9.2 prior to the filing by GNE of an IND on a Licensed Product, SG shall owe GNE royalties on the Net Sales by SG
or its licensees of any Product that would fall under the definition of Licensed Product hereunder as follows: (i) if SG utilizes a construct of an anti-CD40 antibody modified by
GNE (identified in Section 6.2(b)), a [*]% royalty; (ii) if SG utilizes its own construct (identified in Section 6.2(a)) but GNE's cell line, a
[*]% royalty; (iii) if SG does not utilize GNE's construct or cell line, but uses or incorporates any GNE Know-how, a [*]% royalty. 

12

    6.5  Payment of Royalties and Other Amounts. 

    (a) Mode of Payments. For purposes of determining when a sale of any Licensed Product occurs under this Agreement, the
sale shall be deemed to occur on the later of: (i) the date the Licensed Product is shipped; or (ii) the date of the invoice to the purchaser of the Licensed Product. After the date of
Commercial Introduction of the first Licensed Product, all royalty payments shall be made within ninety
(90) days after the end of each calendar quarter in which such sales were deemed to occur. Such royalty payments shall be accompanied by a detailed statement for each country in the Territory
in which sales of Licensed Products occurred in the calendar quarter covered by such statement, specifying: the gross sales (if available) and Net Sales in each country's currency; the applicable
royalty rate under this Agreement; the royalties payable in each country's currency, including an accounting of deductions taken in the calculation of Net Sales; the applicable exchange rate to
convert from each country's currency to U.S. Dollars under Section 6.5(b); and the royalties payable in U.S. Dollars. All payments hereunder shall be made free and clear of any taxes, duties,
levies, fees or charges, except for withholding taxes (to the extent applicable). GNE shall make any applicable withholding payments due on behalf of SG and shall promptly provide SG with written
documentation of any such payment sufficient to satisfy the requirements of the United States Internal Revenue Service related to an application by SG for a foreign tax credit for such payment. All
royalty payments hereunder shall be made to SG in U.S. Dollars by bank wire transfer in immediately available funds to the account designated by SG in writing to GNE from time to time. 

    (b) Foreign Currency Conversion. For sales of any. Licensed Product that occur in a currency other than U.S. Dollars,
the quarterly royalty payment will be calculated as follows: 

    (A/B) × C =
U.S. Dollars royalty payment on foreign currency sales, where 

    A =
foreign currency "Net Sales" per quarter; 

    B =
foreign exchange conversion rate, expressed in local currency per U.S. Dollar (using as the applicable foreign exchange conversion rate the average of the rate published in
the western edition of the Wall Street Journal, or any other mutually agreed-upon source, for the last business day of the calendar quarter); and 

    C =
the royalty rate applicable to such Net Sales under this Agreement. 

    (c) Restrictions on Payment. If by law, regulations or fiscal policy of a particular country in the Territory,
remittance of royalties in U.S. Dollars is restricted or forbidden, written notice thereof will promptly be given to SG, and payment of the royalty shall be made by the deposit thereof in local
currency to the credit of SG in a recognized banking institution designated by SG in writing. When in any country in the Territory the law or regulations prohibit both the transmittal and deposit of
royalties on sales in such country, royalty payments shall be suspended for as long as such prohibition is in effect
and as soon as such prohibition ceases to be in effect, all royalties that GNE would have been under an obligation to transmit or deposit but for the prohibition shall forthwith be deposited or
transmitted to the extent allowable. 

    6.6  Equity Purchases. 

    (a) Initial Purchase. Subject to the other terms of this Agreement, and as consideration to SG for the licenses and
other rights granted to GNE under this Agreement, GNE shall be obligated to purchase up to $2 million of preferred stock of SG in the first offering of such preferred stock to occur after the
Effective Date; provided, however, that SG is not in material breach of this Agreement (or was not at time of termination);  provided, further, that such
offering is completed no later than the second anniversary of Effective Date; and provided,
further, that in no event will GNE be required to purchase stock that would cause GNE to own, in the aggregate, 

13

more than 19.9% of SG's issued and outstanding capital stock. The purchase of stock contemplated by this Section 6.6 shall be effectuated by the Parties entering into a mutually acceptable
stock purchase agreement on terms equivalent to those of the other investors taking part in such offering. Without limitation, the stock purchase agreement and related agreements shall contain:
(i) full registration rights; (ii) transfer rights (subject to compliance with applicable securities laws); (iii) an anti-dilution provision to prevent erosion of
purchase price in the event of another sale of equity, and; (iv) a right of first refusal to newly issued shares to maintain GNE percentage ownership (subject to the carve outs set forth in
SG's Investor Rights Agreement in effect as of the Effective Date); and (v) other provisions that are customary or advisable for similar purchases of preferred equity;  provided, however, that in
the case of all of the foregoing terms, in no event will such terms and conditions be less favorable to GNE than the terms
and conditions contained in SG's Certificate of Incorporation and Investor Rights Agreement in effect as of the Effective Date. GNE will be entitled to review and comment on the documents prepared in
connection with the next equity financing and SG will consider such comments in good faith. SG shall provide GNE with audited and unaudited financial statements and other documents reasonably
requested by GNE (including SG's most recent private financing documents), in connection with the purchase of preferred equity. 

    (b) IPO Support. In addition to the foregoing, and subject to the other terms of this Agreement, GNE shall invest up to
two million dollars ($2,000,000) in an initial public offering of common stock of SG, at the offering price to the public, provided, however, that this
Agreement has not been terminated and that SG is not in material breach of its terms, and provided, further, that in no event will GNE be required to
purchase stock that would cause GNE to own, in the aggregate, more than 19.9% of SG's issued and outstanding capital stock. In lieu of GNE's participation in such initial public offering, if prior to
any such initial public offering GNE files an IND with regard to the Antibodies, SG shall have
the option to cause GNE to invest said two million dollars ($2,000,000) in a private placement purchase of SG's stock; provided, however, that SG must
exercise such option by written notice to GNE within 60 days of the filing date of such IND; and provided, further, that in no event will GNE be required to purchase stock that would cause GNE
to own, in the aggregate, more than 19.9% of SG's issued and outstanding capital stock. [*] 

    6.7  Financial Record Keeping and Review. 

    (a) GNE Records. After the date of Commercial Introduction of the first Licensed Product, GNE shall keep for at least
three (3) years following the end of the calendar year to which they pertain records of all sales of Licensed Products, in sufficient detail to permit SG to confirm the accuracy of GNE's
royalty calculations. 

    (b) Review. Subject to the other terms of this Section 6.7(b), at the request of SG, upon at least fifteen
(15) business days' prior written notice from SG to GNE, and at the expense of SG (except as otherwise provided below), GNE shall permit an independent certified public accountant selected by
SG and reasonably acceptable to GNE to inspect (during regular business hours) the records required to be maintained by GNE under this Section 6.7 as provided herein. At SG's request hereunder
(which shall not be made more frequently than once per year during the Term of this Agreement after the first Commercial Introduction of a Licensed Product and for three (3) years following
expiration or termination of this Agreement), the accountant shall be entitled to review, the then-preceding three (3) years of GNE's records for purposes of verifying GNE's royalty
calculations. In every case the accountant must have previously entered into a 

14

confidentiality agreement with both Parties substantially similar to the confidentiality provisions of Article 8 and limiting the disclosure and use of such information to authorized
representatives of the Parties and the purposes germane to this Section 6.7. Results of any such review shall be made available to both Parties. If any review reveals a deficiency in the
calculation of royalties resulting in any underpayment by GNE, GNE shall promptly pay SG the amount remaining to be paid (plus interest thereon at a rate equal to two percent (2%) over the prime rate
of interest as reported by Bank of America NT&SA in San Francisco, California from time to time), and if such underpayment is by ten percent (10%) or more, GNE shall pay all costs and expenses of the
review. 

  Article 7
       Patent Rights; Trademarks         

    7.1  Definitions. For the purposes of this Article 7, SG Patent Rights and GNE Patents shall not
include patents or applications owned jointly by the Parties. "Joint Patents" shall mean patents and applications therefor owned jointly by the Parties
which cover the manufacture, use or sale of Licensed Products. 

    7.2  Ownership of Intellectual Property. SG shall own all inventions whether or not patentable made
during the course of and pursuant to activities carried out under this Agreement solely by employees of or agents of or others obligated to assign inventions to SG. GNE shall own all inventions made
during the course of and pursuant to activities carried out under this Agreement solely by employees of or agents of or others obligated to assign inventions to GNE. Inventions made during the course
of and pursuant to activities carried out under this Agreement jointly by employees of or agents of or others obligated to assign inventions to SG and GNE shall be jointly owned by GNE and SG. 

    7.3  Disclosure of Inventions. Each Party shall provide to the other, any invention disclosure made
during the course of the performance of this Agreement and related to activities carried out hereunder within thirty days after the Party receives such disclosure from its employees, agents or others
obligated to assign inventions to such Party. 

    7.4  Prosecution of New Patents. 

    (a) GNE
shall have the first right, using in-house or outside legal counsel selected at GNE's sole discretion, to prepare, file, prosecute, maintain and
obtain extensions of GNE Patents or Joint Patents in countries of GNE's choice throughout the Territory. GNE shall bear the costs relating to such activities in the Territory. GNE shall use reasonable
efforts to solicit SG's advice and review of Joint Patents and material prosecution matters related thereto in reasonable time prior to filing thereof, and GNE shall consider in good faith SG's
reasonable comments related thereto. 

    (b) SG
shall have the first right, using in-house or outside legal counsel selected at SG's sole discretion, to prepare, file, prosecute, maintain and
obtain extensions of SG Patents and BMS Patents in countries
of SG's choice throughout the Territory. SG shall use reasonable efforts to solicit GNE's advice and review of SG Patents and material prosecution matters related thereto in reasonable time prior to
filing thereof, and SG shall consider in good faith GNE's reasonable comments related thereto. 

    (c) If
SG, prior or subsequent to filing SG Patents, elects not to file, prosecute or maintain such patents or certain claims encompassed by such patents, SG shall give
GNE notice thereof within a reasonable period prior to allowing such patents or certain claims encompassed by such patents to lapse or become abandoned or unenforceable, and GNE shall thereafter have
the right, at its sole expense to prepare, file, prosecute and maintain such patents or certain claims 

15

encompassed by such patents concerning all such inventions and discoveries in countries of its choice throughout the world. 

    (d) If
GNE, prior or subsequent to filing Joint Patents, elects not to file, prosecute or maintain such patents or certain claims encompassed by such patents, GNE shall
give SG notice thereof within a reasonable period prior to allowing such patents or certain claims encompassed by such patents to lapse or become abandoned or unenforceable, and SG shall thereafter
have the right, at its sole expense to prepare, file, prosecute and maintain such patents or certain claims encompassed by such patents concerning all such inventions and discoveries in countries of
its choice throughout the world. 

    7.5  Prosecution of Existing Patents. In addition, SG shall disclose to GNE all SG inventions conceived
and reduced to practice prior to the Effective Date which cover the manufacture, use or sale of Licensed Products including but not limited to compositions, processes and methods of use of
[*] ("SG Inventions"). SG agrees to keep GNE promptly and fully informed of the course of patent preparation, filing,
prosecution or other proceeding of such SG Inventions including providing GNE with copies of draft applications, applications and substantive communications by or with a domestic or foreign patent
office. SG shall use reasonable efforts to solicit GNE's advice and review of SG Inventions and material prosecution matters related thereto in reasonable time prior to filing thereof, and SG shall
consider in good faith GNE's reasonable comments related thereto. All reasonable costs that SG incurs after the Effective Date in filing, prosecuting and maintaining SG Inventions in the Territory
shall be borne by SG and shall be reimbursed by GNE; provided, however, that GNE shall have the right to determine which countries within the Territory
it will reimburse the costs of filing, prosecuting and maintaining SG Patents. GNE shall have the right to assume responsibility for preparation, filing prosecution and maintaining any SG Patent which
SG intends to abandon or otherwise cause or allow to be forfeited provided that the claims of such SG Invention cover the manufacture use or sale of Licensed Product. SG shall give GNE notice thereof
within a reasonable period prior to allowing such patents or certain claims therein to become abandoned or otherwise forfeited. 

    7.6  Waiver. 

    (a) SG
on behalf of itself and its directors, employees, officers, shareholders, agents, successors and assigns hereby waives any and all actions and causes of action,
claims and demands whatsoever, in law or equity of any kind it or they may have against GNE, its officers, directors employees, shareholders, agents, successors, and assigns, which may arise in any
way except as a result of GNE's gross negligence, recklessness, or willful misconduct in performance of its rights or obligations under Section 7.5 of this Agreement. 

    (b) GNE
on behalf of itself and its directors, employees, officers shareholders agents, successors and assigns hereby waives any and all actions and causes of action,
claims and demands whatsoever, in law or equity of any kind it or they may have against SG, its officers, directors, employees shareholders, agents, successors and assigns, which may arise in any way
except as a result of SG's gross negligence, recklessness, or willful misconduct in performance of its rights or obligations under Section 7.5 of this Agreement. 

    7.7  Infringement. 

    (a) Notice. If either Party learns that a third party is infringing or allegedly infringing any SG Patent Rights or BMS
Patents, it shall promptly notify the other Party thereof including available evidence of infringement. The Parties shall cooperate and use reasonable efforts to stop such alleged infringement without
litigation. 

    (b) Enforcement Actions. SG shall have the first right (but not the obligation) to take the appropriate steps to remove
the infringement or alleged infringement of SG Patent Rights or BMS 

16

Patents, including, without limitation, by initiation, prosecution and control at its own expense of any suit, proceeding or other legal action by counsel of its own choice. GNE shall have the right,
at its own expense, to be represented in any such action by counsel of its own choice. if SG fails to bring an action or proceeding within one hundred eighty (180) days of the later of
(i) notifying GNE of the alleged infringement under Section 7.3(a), (ii) being notified by GNE of the alleged infringement under Section 7.3(a), or (iii) a written
request for such action by GNE, GNE shall have the right (but not the
obligation) to bring any such action or proceeding relating to the SG Patent Rights or BMS Patents by counsel of its own choice, and SG shall have the right, at its own expense, to be represented in
any such action by counsel of its own choice. GNE shall have the first right (but not the obligation) to take the appropriate steps to remove the infringement or alleged infringement of Joint Patents,
including, without limitation, by initiation, prosecution and control at its own expense of any suit, proceeding or other legal action by counsel of its own choice. SG shall have the right, at its own
expense, to be represented in any such action by counsel of its own choice. If GNE fails to bring an action or proceeding within one hundred eighty (180) days of the later of
(i) notifying SG of the alleged infringement under Section 7.3(a), (ii) being notified by SG of the alleged infringement under Section 7.3(a), or (iii) a written
request for such action by SG, SG shall have the right (but not the obligation) to bring any such action or proceeding relating to the Joint Patents by counsel of its own choice, and GNE shall have
the right, at its own expense, to be represented in any such action by counsel of its own choice. If one Party brings any such action or proceeding hereunder, the other Party agrees to be joined as
party plaintiff if necessary to prosecute the action or proceeding and to give the first Party reasonable assistance and authority to file and prosecute the suit; provided,
however, that neither Party shall be required to transfer any right, title or interest in or to any property to the other Party or any other party to confer standing on a Party
hereunder. Any damages or other monetary awards recovered pursuant to any suit, proceeding or other legal action taken under this Section 7.7(b) shall be allocated first to the costs and
expenses of the Party bringing suit, and second to the costs and expenses (if any) of the other Party, with any remaining amounts (if any) to be allocated seventy five percent (75%) to the Party
bringing suit and twenty five percent (25%) to the other Party. 

    7.8  Third Party Patents. (a) if any notice of infringement is received by, or a suit is initiated
against, either Party with respect to any Licensed Product, the Parties shall consult in good faith regarding the best response. If GNE is required to pay any third party with respect to a Licensed
Product or its development, manufacture, use or sale as a result of such action, GNE shall be entitled to offset such payments against the royalties otherwise due and payable by GNE under this
Agreement to SG as provided in Section 6.3. GNE and any sublicensee(s) shall discuss any such third party royalties with SG in advance. 

    (b) [*]

    7.9  Trademarks. All Licensed Products shall be sold in the Territory under trademarks selected and owned
by GNE worldwide. GNE shall control the preparation, prosecution and maintenance of applications related to such trademarks in the Territory, and shall be responsible for the costs of the foregoing.
Each Party shall notify the JOC promptly upon learning of any actual, alleged or threatened infringement of a trademark applicable to a Licensed Product in the Territory, or of any unfair trade
practices, trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory. All of the costs, expenses and legal fees in bringing, maintaining and prosecuting any action to
maintain, protect or defend a jointly owned Trademark in the Territory, and any recovery, shall be GNE's responsibility. 

17

  Article 8
       Confidentiality         

    8.1  Confidential Information. In the course of performance of this Agreement, one Party may disclose to
the other or receive written information from the other relating to the subject matter of this Agreement which information, if so identified in writing either pursuant to this Section 8.1 or
otherwise upon disclosure, shall be considered to be the disclosing Party's "Confidential Information". Each Party agrees that it will take the same
steps to protect the confidentiality of the other Party's Confidential Information as it takes to protect its own proprietary and confidential information. Each Party shall protect and keep
confidential and shall not use, publish or otherwise disclose to any third party, except as contemplated by this Agreement or with the other Party's prior written consent, the other Party's
Confidential Information for a period of five (5) years from the date of disclosure to it pursuant to this Agreement. For purposes of this Agreement, Confidential Information shall not include
such information that: 

    (a) was
known to the receiving Party at the time of disclosure of it to the receiving Party by the disclosing Party hereunder; or 

    (b) was
generally available to the public or was otherwise part of the public domain at the time of disclosure or became generally available to the public or otherwise
part of the public domain after disclosure other than through any act or omission of the receiving Party in breach of this Agreement; or 

    (c) became
known to the receiving Party after disclosure from a source that had a lawful right to disclose such information to others; or 

    (d) was
independently developed by the receiving Party where such independent development can be established by written documentation. 

    8.2  Permitted Disclosure. Each Party shall be entitled to disclose Confidential Information of the other
Party to consultants and other third parties for any purpose provided for in this Agreement, provided that any such other party has first agreed in writing to confidentiality restrictions and
obligations at least as protective as this Section 8. SG shall be entitled to disclose Confidential Information (including the terms of this Agreement) to prospective investors in connection
with its financing activities, so long as they are subject to appropriate confidentiality obligations. Either Party shall consult with the other Party prior to the submission of any manuscript for
publication if the publication will contain any Confidential Information of the other Party, unless the laws and regulations applicable to any third party submitting such manuscript prohibit such
consultation. Such consultation shall include providing a copy of the proposed manuscript to the other Party at least sixty (60) days prior to the proposed date of submission to a publisher,
incorporating appropriate changes proposed by the other Party as to its Confidential Information into the manuscript submission and deleting all Confidential Information of the other Party as it may
request. Notwithstanding the foregoing, Confidential Information of either Party may be disclosed by the other Party as a part of a patent application filed on inventions made under this Agreement and
during any official proceeding before a court or governmental agency if related and necessary to that proceeding. 

    8.3  Integration. This Section 8 supersedes any confidential disclosure agreement between the
Parties as to the subject matter hereof Any confidential information under any such agreement shall be treated as Confidential Information hereunder. 

    8.4  Survival. This Section 8 shall survive termination or expiration of this Agreement. 

18

  Article 9
       Term; Expiration; Termination         

    9.1  Term; Expiration. This Agreement shall commence as of the Effective Date and, unless sooner
terminated as provided hereunder, shall expire on a country-by-country and Licensed Product-by-Licensed Product basis upon the later of
(i) [*] ([*]) years from the date of Commercial Introduction of such Licensed Product in such country and (ii) the
[*]. The period from the Effective Date through expiration
as provided herein as to every Licensed Product in every country in the Territory is defined as the "Term". Provided the license to GNE has not
previously been terminated under this Agreement, upon expiration of the royalty obligations as to any Licensed Product in any country, GNE shall thereafter have in perpetuity a fully paid up,
royalty-free, non-exclusive license in that country to use the SG Know-how and practice the SG Patent Rights to use, market and sell that Licensed Product without
any accounting to SG. 

    9.2  Unilateral Termination. GNE shall have the right to terminate this Agreement at any time for any
reason effective ninety (90) days after written notice to SG, except for SG's material breach which shall be governed by Section 9.3. SG shall have the unilateral termination rights set
forth in Section 3.3(c) above. Remedies for unilateral termination are specified in Section 3.3(c). 

    9.3  Breach. Subject to Section 3.3, which shall prevail over this Section 9.3 with respect
to due diligence defaults by GNE, failure by either Party to comply with any of the material obligations contained in this Agreement shall entitle the other Party (the  "Non-Defaulting Party") to give to
the Party (the "Defaulting Party") in default written
notice specifying the nature of the default and requiring it to make good such default. If such default is not cured within ninety (90) days after the receipt of such notice, the
Non-Defaulting Party shall be entitled, without prejudice to any other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity,
immediately to terminate this Agreement by giving written notice to the Defaulting Party. The right of a Party to terminate this Agreement, as hereinafter provided, shall not be affected in any way by
its waiver or failure to take action with respect to any previous default. 

    9.4  Insolvency or Bankruptcy. Either Party may, in addition to any other remedies available to it by law
or in equity, terminate this Agreement effective on written notice to the other Party in the event the other Party shall have become insolvent or bankrupt, or shall have made an assignment for the
benefit of its creditors, or there shall have been appointed a trustee or receiver of the other Party or for all or a substantial part of its property, or any case or proceeding shall have been
commenced or other action taken by or against the other Party in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up, arrangement, composition or readjustment of its
debts or any other relief under any bankruptcy, insolvency, reorganization or other similar act or law of any jurisdiction now or hereafter in effect, or there shall have been issued a warrant of
attachment, execution, distraint or similar process against any substantial part of the property of the other Party, and any such event shall have continued for ninety (90) days undismissed,
unbonded and undischarged. Furthermore, all rights and licenses granted under this Agreement are, and shall be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of
rights to "intellectual property" as defined under Section 101(56) of the United States Bankruptcy Code. The Parties agree that in the event of the commencement of a bankruptcy proceeding by or
against one Party hereunder under the United States Bankruptcy Code, the other Party shall be entitled to complete access to any such intellectual property, and all embodiments of such intellectual
property, pertaining to the rights granted in the licenses hereunder of
the Party by or against whom a bankruptcy proceeding has been commenced; subject, to payment of the milestone amounts and royalties set forth in this Agreement. 

19

    9.5  Effect of Expiration or Termination. 

    (a) Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement for any reason shall be without
prejudice to any rights which shall have accrued to the benefit of either Party prior to such termination or expiration, and shall not relieve either Party from its obligations which are expressly
indicated to survive expiration or termination of this Agreement, including, without limitation, those under Sections 3.3(c), 3.9(b), 3.9(c), 6.6(a), 6.7, 7.2, 7.6, 9.5, and Articles 8, 10 and 12. 

    (b) Continued Rights; Supply. On any termination of this Agreement by GNE under Section 9.3, GNE thereafter
automatically shall have a fully paid up exclusive license in the Territory to use the SG Know-how and practice the SG Patent Rights to make, have made, use, market and sell Licensed
Products in the Field in the Territory; provided that GNE shall pay, for the remainder of the life of the relevant SG Patent in the relevant country, in lieu of any payments including royalties it
would otherwise owe to SG, a royalty in the amount of [*] percent ([*]%) of Net Sales of License Products. 

    (c) Sublicenses. No termination of this Agreement (except by GNE under Section 9.2 above) shall be construed as a
termination of any valid sublicenses granted by GNE under Section 5.3, and thereafter each such sublicensee shall be a direct licensee of SG, provided that such sublicensee is then in full
compliance with all terms and conditions of its sublicense, all payments owed thereunder to SG have been paid, and such sublicensee agrees at least ten (10) days prior to the effective date of
termination of this Agreement to assume all obligations of GNE under this Agreement. 

    (d) BMS Patents. Upon any termination of this Agreement (other than due to breach by SG) or the BMS Agreement, all
rights to BMS Patents granted to GNE in Section 5.1(b) shall terminate simultaneously, provided, however, that in the event of a termination of
the BMS Agreement, SG shall use its best efforts to secure on behalf of GNE a continuation of the licenses set forth in Section 5.1(b). 

    (e) Clinical Data. Except with regard to clinical trials conducted by SG on SGN 11&12, all data produced as a result of
clinical trials conducted under this Agreement shall be owned by GNE, except
to the extent in conflict with the requirements of the FDA or any Foreign Regulatory Authority, and all such data shall be considered Confidential Information of GNE. GNE or any sublicensee(s) it
shall designate shall be named as the applicant in any filing for any Regulatory Approval made hereunder, and shall be the holder of all such Regulatory Approvals. Such ownership and status as
applicant and holder shall survive any expiration or termination of this Agreement. 

  Article 10
       Indemnification         

    10.1  Indemnification by GNE. GNE hereby agrees to save, defend and hold SG and its agents and employees
harmless from and against any and all suits, claims, actions, demands, liabilities, expenses and/or loss, including reasonable legal expense and attorneys' fees
("Losses") resulting directly from GNE's or any sublicensee's manufacturing of the Antibodies, performance of work under any agreed upon Development
Plan, or testing, labeling, marketing, use or sale of Licensed Products in the Territory, except to the extent such Losses result from the negligence or willful misconduct of SG. 

    10.2  Indemnification by SG. SG hereby agrees to save, defend and hold GNE and its agents and employees
harmless from and against any and all Losses resulting directly from SG's performance of work under any agreed upon Development Plan, except to the extent such Losses result from the negligence or
willful misconduct of GNE. 

20

    10.3  Notice. In the event that one Party is seeking indemnification under this Section 10 (the
"Indemnified Party"), it shall inform the other Party (the "Indemnifying Party") of a claim as soon as
reasonably practicable after the Indemnified Party receives notice of the claim, shall permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to
settle the claim solely for monetary consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. 

    10.4  Insurance. (a)(i) Commencing on the Effective Date and thereafter for the period of time
required hereinbelow, each Party shall obtain and maintain on an on-going basis comprehensive general liability insurance in the amount of $[*] per occurrence and
$[*] annual aggregate combined single limit for bodily
injury and property damage liability; (ii) commencing not later than 30 days prior to the first use in humans of the first potential Licensed Product and thereafter for the period of
time required hereinbelow, each Party shall provide and maintain on an on-going basis products liability insurance (including contractual liability coverage on each Party's indemnification
obligation under this Agreement) in the amount of at least $[*] per occurrence and annual aggregate combined single limit for bodily injury and property damage liability. All
of such insurance coverage shall be maintained with a insurance company or companies having an A. M. Best rating of "A-" or better and an aggregate deductible not to exceed
$[*] per occurrence. 

    (b) Not
later than the Effective Date with respect to the comprehensive general liability coverage, and not later than 30 days prior to the first use in humans
of the first potential Product with respect to the products liability coverage, each Party shall provide to the other Party certificates evidencing all such required coverage hereunder. Thereafter
each Party shall maintain such insurance coverage without interruption during the term of this Agreement and for a period of at least 10 years after the expiration or termination of the term
and shall provide certificates evidencing such insurance coverage without interruption on an annual basis (by no later than the annual renewal date for such coverage) during the period of time for
which such coverage must be maintained. 

    (c) Each
Party's insurance shall name the other Party as an additional insured, shall state that such insurance is primary to any valid and collectible insurance
available to the other Party that also insures the same loss for which the first Party has liability pursuant to this Agreement (including, without limitation, under the indemnification provisions
hereof), shall contain a cross-liability or severability of interest clause, and shall state that the other Party shall be provided at least 60 days' prior written notice of any cancellation or
material change in the insurance policy. 

    10.5  Survival. This Section 10 shall survive termination or expiration of this Agreement. 

  Article 11
       Representations and Warranties         

    11.1  Representations and Warranties of SG. SG hereby represents and warrants that: 

    (a) the
execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate SG corporate
action; 

    (b) this
Agreement is a legal and valid obligation binding upon SG and enforceable in accordance with its terms. The execution, delivery and performance of the
Agreement by SG does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate in any material respect any law or
regulation of any court, governmental body or administrative or other agency having jurisdiction over it; 

    (c) SG
has the rights to transfer to GNE all materials contemplated by this Agreement to be so transferred, including, without limitation, [*]
(SGN 14), and GNE has the sufficient rights pursuant to this Agreement to use such materials for the purposes hereof; 

21

    (d) SG has the right to grant the licenses granted in Section 5.1, and has no knowledge of any rights of any third parties that would interfere with the use of
the SG Know-how or practice of the SG Patent Rights or the BMS Patents by GNE as contemplated under this Agreement; and 

    (e) SG
has no knowledge as of the Effective Date from which it can be inferred that any patents or patent applications within the SG Patent Rights or the BMS Patents
are invalid or unenforceable or that their exercise would infringe patent rights of third parties. 

    11.2  Representations and Warranties of GNE. GNE represents and warrants that: 

    (a) the
execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate GNE corporate
action; and 

    (b) this
Agreement is a legal and valid obligation binding upon GNE and enforceable in accordance with its terms. The execution, delivery and performance of the
Agreement by GNE does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is
bound, nor violate in any material respect any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

    11.3  Survival. The representations, warranties, covenants and agreements made herein shall survive any
investigation made by a Party and shall be able to be relied fully on by the Parties. 

  Article 12
       Miscellaneous Provisions         

    12.1  No Partnership. Nothing in this Agreement is intended or shall be deemed to constitute a
partnership, agency, distributorship, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent,
if at all, specifically provided herein. 

    12.2  Assignments. Neither Party shall assign any of its rights or obligations hereunder except:
(a) as incident to the merger, consolidation, reorganization or acquisition of stock or assets affecting substantially all of the assets or voting control of the assigning Party; (b) to
any wholly owned subsidiary if the assigning Party remains liable and responsible for the performance and observance of all of the subsidiary's duties and obligations hereunder; or (c) with the
prior written consent of the other Party (which consent shall not be unreasonably withheld). This Agreement shall be binding upon the successors and permitted assigns of the Parties, and the name of a
Party appearing herein shall be deemed to include the names of such Party's successor's and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in
accordance with this Section 12.2 shall be void. 

    12.3  Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments,
and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

    12.4  Use of Names. Except as otherwise provided herein, no right, express or implied, is granted by this
Agreement to use in any manner the names "Seattle Genetics" or "Genentech" or any other trade name or trademark of SG or GNE in connection with the performance of this Agreement. 

    12.5  Public Announcements. Except as may otherwise be required by law or regulation, neither Party shall
make any public announcement concerning this Agreement or the subject matter hereof 

22

without the prior consent of the other Party unless the nature of the information has been previously approved for disclosure. If the nature of the information has been approved, this
Section 12.5 will no longer apply to that information. 

    12.6  Entire Agreement; Amendments. This Agreement constitutes and contains the entire understanding and
agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether verbal or written, between the Parties respecting the subject
matter hereof, including, without limitation, the Previous Agreement. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and
signed by a duly authorized representative of each of the Parties. 

    12.7  Severability. In the event any one or more of the provisions of this Agreement should for any
reason be held by any court or authority having jurisdiction over this Agreement or either of the parties to be invalid, illegal or unenforceable, such provision or provisions shall be validly
reformed to as nearly as possible approximate the intent of the Parties and, if unreformable, shall be divisible and deleted in such jurisdiction; elsewhere, this Agreement shall not be affected so
long as the Parties are still able to realize the principal benefits bargained for in this Agreement. 

    12.8  Captions. The captions to this Agreement are for convenience only, and are to be of no force or
effect in construing or interpreting any of the provisions of this Agreement. 

    12.9  Applicable Law. This Agreement shall be governed by and interpreted in accordance with the laws of
the State of Washington applicable to contracts entered into and to be performed entirely within the State of Washington. 

    12.10  Notices and Deliveries. Any notice, requests, delivery, approval or consent required or permitted
to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by telecopy with a confirming copy sent by overnight
courier or
registered mail to the Party to whom it is directed at its address shown below or such other address as such party shall have last given by notice to the other Party. Any such notice, requests,
delivery, approval or consent shall be deemed received on the date of telecopy or hand delivery, one business day after deposit with an overnight courier, or 3 days after deposit of the
registered mail with the U. S. postal service. 

	If to SG,

addressed to:	 	SEATTLE GENETICS, INC.

22215 26th Avenue SE

Bothell, Washington 98021

Attention: Chief Executive Officer

Telephone: (425) 489-4990

Telecopy: (425) 489-4798
	 

 	 
 	 

with a copy to: Chief Scientific Officer
	 
 If to GNE,

addressed to:	 
 	 

GENENTECH, INC.

I DNA Way

South San Francisco, CA 94080

Attention: Corporate Secretary

Telephone: (650) 225-1000

Telecopy: (650) 952-9881

    12.11  Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other Party for
damages or losses on account of failure of performance by the defaulting Party if the failure is occasioned by government action, war, earthquake, fire, explosion, flood, strike, lockout, embargo, act 

23

of God, or any other cause beyond the control of the defaulting Party, provided that the Party claiming force majeure has exerted all reasonable efforts to avoid or remedy such force majeure;  provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance.
 

    12.12  Dispute Resolution. The Parties shall attempt to settle any dispute, controversy or claim arising
out of or relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any determination as
to the validity of the Parties' patents (hereinafter, the "Dispute"), in accordance with the provisions of this
Section 12.12. The Parties have entered into the Agreement in good faith and in the belief that it is mutually advantageous to them. It is with that same spirit of cooperation that they pledge
to attempt to resolve any Dispute amicably. Accordingly, the Parties agree that if any Dispute should arise, the JOC shall attempt to resolve it as contemplated in Section 2.1(c) above. If the
JOC is unable to resolve the Dispute, it shall then be referred to a member of senior management from each of the Parties and from any GNE sublicensee (if any). If those individuals are unable to
resolve the disagreement, the Parties may seek to mediate their Dispute by mediation, with a mediator mutually agreeable between the Parties. 

    12.13  Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

[Signature
page follows.] 

24

    IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as of Effective Date. 

	SEATTLE GENETICS, INC.	 	GENENTECH, INC.
	 

By:	 
 	 

/s/ H. PERRY FELL   	 
 	 

By:	 
 	 

/s/ NICOLAS J. SIMON   
	 	 	
	 	 	 	

	 

Name:	 
 	 

H. Perry Fell	 
 	 

Name:	 
 	 

Nicolas J. Simon
	 	 	
	 	 	 	

	 

Title:	 
 	 
 President and C.E.O.	 
 	 

Title:	 
 	 
 Vice President
	 	 	
	 	 	 	

SIGNATURE PAGE TO DEVELOPMENT AND LICENSE AGREEMENT  

25

QuickLinks

DEVELOPMENT AND LICENSE AGREEMENT

GENENTECH, INC. AND SEATTLE GENETICS, INC.

Recitals

Article I Definitions

Article 2 Management of Development

Article 3 Development

Article 4 Commercialization in the Territory

Article 5 Licenses; Grants of Rights

Article 6 Milestones and Royalties; Equity Purchases

Article 7 Patent Rights; Trademarks

Article 8 Confidentiality

Article 9 Term; Expiration; Termination

Article 10 Indemnification

Article 11 Representations and Warranties

Article 12 Miscellaneous ProvisionsPrepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document
 

Exhibit 10.18

Confidential treatment requested  

    This Agreement, dated as of 24 January 2000 is between Genentech, Inc., a Delaware corporation having a principal place of business 1 DNA Way,
South San Francisco, California 94080 (hereinafter "Genentech") and Seattle Genetics Inc., having a place of business at 22215 26th Ave. S.E. Bothell, WA 98021 (hereinafter "Licensee'). 

WHEREAS: 

	A.
	Genentech
is the owner of certain patents and patent applications (patent rights) relating to methods and compositions in the field of immunoglobulins.

	B.
	Genentech
does not wish to have these patent rights hinder the development of immunoglobulin products and is willing to grant licenses for the development of products for public use
and benefit as specified in this Agreement.

	C.
	Licensee
desires to obtain a license under the terms and conditions specified herein.

	D.
	Genentech
and Licensee believe that the subject matter of this license will be most effectively commercialized under conditions of limited exclusivity to encourage the investments
required to develop and market such subject matter. 

NOW,
THEREFORE, the parties agree as follows: 

  Article I
       DEFINITIONS        

    Unless
otherwise specifically set forth herein, the following terms shall have the following meanings: 

    1.01.  "Affiliate" of Licensee shall mean any entity that controls, is controlled by or is under common
control with Licensee; and "control" for purposes of this definition shall mean the possession of the power to direct or cause the direction of the management and policies of an entity, whether
through the ownership of voting stock, by contract or otherwise. In the case of a corporation, "control" shall mean the direct or indirect ownership of fifty percent (50%) or more of the outstanding
voting stock together with a controlling membership on the board of directors of such corporation. 

    1.02.  "Antigen" as used in this Agreement shall mean a substance listed in Schedule A attached
hereto and made a part of this Agreement. Schedule A may be amended from time to time by mutual agreement of the Parties in writing, at which time the financial terms pertaining to the newly
added Antigen(s) may also be modified. 

    1.03.  "Bulk Product" shall mean Licensed Product supplied in a form other than Finished Product which
can be converted into Finished Product. 

    1.04.  "Cost of Product" shall mean the cost of acquisition, if purchased, or the cost of manufacture,
the latter being the sum of direct production costs and manufacturing overhead costs determined in accordance with generally accepted accounting principles. 

    1.05.  "Designee" shall mean a person or entity designated by a Party to exercise the rights of and
perform obligations hereunder in place of and to the exclusion of that Party in the Territory or a portion thereof. 

[*]   Confidential treatment requested 

1

    1.06.  "Effective Date" shall mean as to each Antigen, or Licensed Product based thereon, the later of
the date of this Agreement or the date on which such Antigen was added to Schedule A by amendment. 

    1.07.  "Field" shall mean the manufacture, use or sale of Licensed Product for the prevention or therapy
of human diseases. 

    1.08.  "Finished Product" shall mean any and all Licensed Products in form for use by an end user and
not intended for further chemical or genetic manipulation or transformation. 

    1.09.  "Licensed Patents" shall mean 

U.S.
Patent No. 4,816,567 and the claims relating to chimeric antibodies found in patents or patent applications arising from divisionals, continuations or
continuations-in-part of any application from which U.S. Patent No. 4,816,567 claims priority (excluding U.S.S.N. 07/205,419 and foreign counterparts thereof) as well as
the foreign counterparts of the foregoing and any and all reissues, reexaminations or extensions of the foregoing ("Chimera Patents"). 

Licensee
hereby acknowledges they have specifically declined to license any patent issuing based on U.S.S.N. 07/205,419 (a continuation of the application maturing into U.S. Patent
No. 4,816,567) relating to the coexpression of immunoglobulin chains in recombinant host cells, as well as the divisionals, continuations or continuations-in-part of
such U.S.S.N. 07/205,419, the issued foreign counterparts of such U.S.S.N. 07/205,419 and any and all reissues, reexaminations or extensions of the foregoing ("Coexpression Patents"). 

Attached
hereto as Schedule B is a list of patents and patent applications that Genentech in good faith believes represents Licensed Patents as of the end of 1998. However no warranty is given
as to the completeness or accuracy of Schedule B or any update thereof that might subsequently be provided to licensee. 

    1.10.  "Licensed Product(s)" shall mean substances capable of binding to an Antigen listed in
Schedule A hereto, the manufacture, use or sale of which substances would, if not licensed under this Agreement, infringe one or more claims of Chimera Patents, which have neither expired nor
been held invalid by a court or other body of competent jurisdiction from which no appeal has been or may be taken. 

    1.11.  "Net Sales" shall mean the gross invoice or contract price to third party customers for Finished
Products. Finished Products used or consumed by Licensee or its Affiliates or Designees as part of the delivery of services to customers shall be considered Net Sales at the gross invoice or contract
price of like Finished Products which are sold to customers. If Licensed Product is sold in combination with one or more active ingredients, Net Sales shall be calculated by multiplying Net Sales of
the combination product by the fraction A/(A+B) where A is the sales price of the Finished Product in the combination when sold separately and B is the total sales price of all other active
ingredients in the combination when sold separately. If the Finished Product and the other active ingredients are not sold separately, the percentage of the total cost of the combination product
attributed to Cost of Product shall be multiplied times the sales price of the combination product to arrive at Net Sales. For all Licensed Product used or consumed by others than Licensee, Licensee
shall be entitled to deduct [*]% from Net Sales in lieu of all other deductions such as taxes, shipping charges, allowances and the like prior to calculating royalties due. 

    Net
Sales for Bulk Products shall be calculated by doubling the gross invoice or contract price of Bulk Products sold to non-affiliated customers. 

    The
method of calculating Net Sales of materials in form other than Finished Product or Bulk Product that can be converted into Finished Product shall be established by the Parties
prior to the first sale or transfer of any such material by Licensee to a non-affiliated third party. 

2

    1.12.  "Party" shall mean Genentech or Licensee and when used in the plural shall mean Genentech and
Licensee. 

    1.13.  "Territory" shall mean the entire world. 

  Article II
       GRANT        

    2.01.  License.  Subject to the fulfillment by Licensee
of all the terms and conditions of this Agreement, Genentech hereby grants to Licensee and Licensee hereby accepts a coexclusive license together with the right to sublicense its Affiliates and
Designees under Licensed Patents for the term thereof to make, use and sell Licensed Products in the Field and the Territory. This grant shall be coexclusive with Genentech, Inc., and
additional licensees, if any, to be selected solely by Genentech. Genentech shall be free at its discretion to enter into agreements with such additional licensees at any time and on terms solely of
its choosing. However, Genentech represents that, unless for a particular Antigen a different number of additional licenses is specified at the time such Antigen is included in Schedule A, it
will not grant more than four (4) additional licenses in which both the Field and Territory are coextensive with that which is set forth herein. 

    2.02.  Right to Appoint Designee.  Licensee shall have
the right to sublicense all of its rights hereunder for all or part of the Territory (including on a country-by-country basis) to a Designee of its choosing, to the exclusion
of Licensee in such Territory or portion thereof, provided that Licensee agrees that it will indemnify Genentech for any failure of performance on the part of such Designee. An entity that simply acts
to co-promote or to co-market Licensed Product supplied by Licensee shall not be considered a Designee and Licensee may co-promote or co-market such
Licensed Product with such entity in a given country or countries, provided that (i) both Licensee and such entity obtain Licensed Products from the same manufacturing source, (ii) only
one such entity shall be permitted to co-promote or co-market the same Licensed Product in a given country, and (iii) Licensee shall be responsible for the payment of
royalties on Net Sales of Licensed Products by such entity and for all other acts of such entity as if such acts were those of the Licensee. 

    2.03.  No Other License.  Licensee understands and agrees
that no license under any patent or application other than Licensed Patents is or shall be deemed to have been granted under this Agreement, either expressly or by implication. 

    2.04.  Licenses Separately Available.  Licensee
acknowledges that separate licenses under Chimera Patents and Coexpression Patents were available from Genentech and that Licensee specifically declined to license Coexpression Patents. Licensee
further acknowledges that it was not coerced to enter into a license under either one of Chimera or Coexpression Patents as a condition to obtaining a license under the other, and that the licenses
hereunder were not offered as a mandatory package. Licensee
understands that no assurances can be given that Coexpresion Patent licenses for any given Antigen will be available in the future or that the same or similar terms will be available to any Licensee
in the future. 

  Article III
       FEES AND ROYALTIES        

    3.01.  License Grant Fee.  

    (a) Within
sixty (60) days after execution of this Agreement, Licensee shall pay to Genentech a non-creditable, non-refundable initial
installment license grant fee of $[*] and 

3

    (b) Within thirty (30) days of filing an NDA or BLA or equivalent for any indication, Licensee shall pay to Genentech a non-creditable,
non-refundable final installment license grant fee of $[*]. 

    3.02.  Minimum Annual Royalties.  Licensee shall pay to
Genentech a minimum annual royalty for each Antigen on or before January 31 of each year beginning with the [*] full calendar year after the Effective Date for such
Antigen in accordance with the following table: 

	Full Calendar Year
	 	Minimum Annual Royalty

	[*]	 	$[*]
	[*]	 	$[*]
	[*]	 	$[*]
	[*]	 	$[*]

Such
payments shall be non-refundable but shall be creditable against earned royalties as provided in Section 3.05. 

    3.03.  Earned Royalties.  

    Licensee
shall pay to Genentech a royalty of [*] percent ([*]%) for Chimera Patents on Net Sales of Licensed Products sold by Licensee
and its sublicensees. 

    3.04.  Sales To and Between Sublicensees.  No royalties
shall be due upon sales of Licensed Products to and between Licensee, its Affiliates, its sublicensees, co-promoting parties or co-marketing parties as permitted under
Section 2.02 for further sale; provided, however, that the royalty hereunder shall be payable upon the final sale by any of the foregoing to a non-affiliated vendee. 

    3.05.  Credits Against Royalties.  

    (a) Licensee
shall be entitled to reduce the earned royalty payment due under Section 3.03 for a given Antigen by up to [*] percent
([*]%) by applying as a one-time credit against such royalty (i) the [*] paid for such Antigen for the calendar year for which earned
royalties are then due and (ii) an amount equal to the cumulative payments previously made under Section 3.02 for the [*] ([*]) years
immediately preceding the calendar year in which Licensee [*] in [*] of a particular Licensed Product for so long as is necessary to amortize such
cumulative payments. Credits earned for one Antigen are not applicable to royalties due for other Antigens. 

    (b) Licensee
may apply as a credit against royalties owed to Genentech for any Licensed Product pursuant to Section 3.03 up to [*] of
royalties actually paid during the relevant quarter to any third party for the same Licensed Product pursuant to a license agreement for the third party's patent rights covering such License Product,
including royalties paid to the [*] with respect to valid and enforceable claims of [*] or foreign counterparts thereof. 

    (c) In
no event shall the credits taken pursuant to subparagraphs (a) and (b) of this Section 3.05 taken in the aggregate exceed
[*] percent ([*]%) of the royalties owed to Genentech for any reporting quarter. 

    3.06.  No Non-Monetary
Consideration.  Without the prior written consent of Genentech, Licensee and its Affiliates shall not solicit or accept any consideration for the sale of any
Licensed Product other than as will be accurately reflected in Net Sales. 

    3.07.  [*]  

4

  Article IV
       RECORDS, REPORTS AND PAYMENTS        

    4.01.  Records Retention.  Licensee shall keep and shall
cause its sublicensees to keep records of the sales of all Licensed Products in sufficient detail to permit Genentech to confirm the accuracy of Licensee's royalty calculations. At Genentech's request
and expense, Licensee shall permit an independent certified public accountant appointed by Genentech and acceptable to Licensee to examine, upon reasonable notice and at reasonable times, such records
solely to the extent necessary to verify Licensee's calculations. Such examination shall be limited to a period of time no more than three (3) years immediately preceding the request for
examination. If Licensee's royalties are found to be in error such that royalties to Genentech were underpaid by more than five (5) percent then Licensee shall promptly pay any deficiency, plus
interest at the prime rate, to Genentech and reimburse Genentech for its costs in examining such records. 

    4.02.  Reports.  Within sixty (60) days after the
end of each calendar quarter following Licensee's or its sublicensee's first sale of Licensed Product, Licensee shall furnish to Genentech a written report of all sales of Licensed Products subject to
royalty under Section 3.03 during such calendar quarter. Such report shall include (i) the determination of Net Sales as specified in Section 1.11; (ii) detailed
itemization of the credits taken pursuant to Section 3.05; and (iii) the royalty payment then due. 

    4.03.  Payments.  Concurrently with each report pursuant
to Section 4.02, Licensee shall make the royalty payment then due. Payments shall be in United States dollars and, unless otherwise agreed in writing, shall be made by wire transfer to such
bank as Genentech may from time to time designate in writing, without set-off and free and clear of and without any deduction or withholding for or on account of any taxes, duties, levies,
imposts, fees or charges except for withholding required by tax authorities for income taxes on royalties actually payable to Genentech after application of the credits permitted by Sections 3.05.
Licensee shall make any withholding payments due on behalf of Genentech and shall promptly provide Genentech with official tax receipts or other written documentation sufficient to enable Genentech to
satisfy the United States tax authorities with respect to Genentech's application for a foreign tax credit for such payment. 

    4.04.  Currency Conversion.  Royalties due on Net Sales
of Licensed Products made in currency other than United States dollars shall first be calculated in the foreign currency and then converted to United States dollars on the basis of the rate of
exchange in effect for purchase of dollars published in the Wall Street Journal on the last business day of the period for which royalties are due. 

  Article V
       LIABILITY        

    5.01.  Indemnification.  Licensee shall defend, indemnify
and hold Genentech harmless against any and all liability, damage, loss, cost or expense resulting from any claim, suit or other action arising out of or based on the manufacture, use or sale of any
Licensed Product by Licensee, its sublicensees or co-promoting or co-marketing entities pursuant to Section 2.02; provided, however, that upon the filing of any such
claim or suit, Genentech shall promptly notify Licensee and permit Licensee, at Licensee's cost, to handle and control such claim or suit and shall cooperate in the defense thereof. 

  Article VI
       PATENT INFRINGEMENT        

    6.01.  Notification of Infringement.  Licensee shall
notify Genentech of any infringement by third parties of any patent within Licensed Patents of which Licensee is aware and shall provide Genentech with the available evidence, if any, of such
infringement. 

5

    6.02.  Enforcement of Licensed Patents.  Genentech shall
retain the sole right, at its sole discretion and expense, to enforce Licensed Patents against third party infringers. However, if (i) a non- Affiliated third party which is not
licensed under Chimera Patents or Coexpression Patents attains a market share of the greater of (a) at least [*] percent ([*]%) of sales (in
monetary volume) or (b) [*] dollars ($[*]) in sales of a particular Licensed Product within the Field in any country, (ii) Licensee or its
sublicensee is selling the Licensed Product in such country, (iii) there is reasonable evidence that such third party is infringing either Chimera Patents or Coexpression Patents under which
Licensee is paying royalties, (iv) Licensee has paid and is not in arrears in the payment to Genentech of all royalties due under this Agreement and (v) Genentech fails to take action to
abate the infringement within six (6) months after receipt of notice pursuant to Section 6.01, then Licensee shall be entitled to reduce the royalty rates to [*]
([*]) of the rates otherwise set forth in Section 3.03 for the country in which the qualifying infringement exists. Such reduction shall continue until such time as
Genentech takes action to abate the infringement or until the market share of such third party drops below ten percent of the total market or sales below [*] dollars for that
particular Licensed Product within the Field in the country in question. Royalties shall not be affected in countries in which such infringement is not occurring. Unlicensed infringing sales shall not
affect the payment under Section 3.01. Unlicensed infringing sales shall not affect minimum royalties under Section 3.02 unless such sales constitute greater than
[*] percent ([*]%) of the market for such particular Licensed Product in all markets in which Licensee and its sublicensees sell the Product, in which
case the otherwise appropriate minimum shall be reduced by the percentage market share held by the unlicensed infringer. Genentech shall be entitled to recovery of all damages, costs and the like in
any action brought under this Section 6.02. 

    6.03.  No Warranty of
Non-Infringement.  Nothing in this Agreement shall be construed as a representation made or warranty given by Genentech that the practice by Licensee
or its sublicensees of the license granted hereunder will not infringe the patent rights of any third party. 

  Article VII
       TERM AND TERMINATION        

    7.01.  Term.  This Agreement shall come into force as of
its Effective Date and shall continue in full force and effect on a country-by-country basis unless earlier terminated as provided herein or until the expiration of the last to
expire of the Licensed Patents. 

    7.02.  Termination for Breach.  Genentech shall have the
right to terminate this Agreement and the licenses granted hereunder upon thirty (30) days' written notice to Licensee for Licensee's material breach of this Agreement if Licensee has failed to
cure such breach within thirty (30) days of notice thereof. 

    7.03.  Insolvency.  Either Party may terminate this
Agreement if, at any time, the other Party shall file in any court pursuant to any statute of any individual state or country, a petition in bankruptcy, insolvency or for reorganization or for an
agreement among creditors or for the appointment of a receiver or trustee of the Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or
if the other Party shall be served with an involuntary petition against it filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing
thereof, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of creditors. 

    7.04.  Termination by Licensee.  Licensee may terminate
this Agreement in its entirety or with respect to one or more Antigens at any time upon six (6) months' written notice to Genentech. 

    7.05.  Effect of Termination.  Termination of this
Agreement in whole or in part for any reason shall not relieve Licensee of its obligations to pay all fees and royalties that shall have accrued hereunder prior to the effective date of termination.
Termination of this Agreement as to Licensee 

6

shall result in the termination of the licenses of Licensee and all sublicensees of Licensee. The provisions of Sections 5.01 shall survive termination of the Agreement for any reason except
termination for breach by Genentech. 

  Article VIII
       MISCELLANEOUS PROVISIONS        

    8.01.  Limitations on Assignments.  Neither this
Agreement nor any interests hereunder shall be assignable by either Party without the written consent of the other; provided, however, that either Party may assign this Agreement to any corporation or
entity with which it may merge or consolidate, or to which it may transfer substantially all of its assets or all of its assets to which this Agreement relates without obtaining the consent of the
other Party. 

    8.02.  Jurisdiction and Choice of Laws.  This Agreement
shall be interpreted and construed under the laws of California, and Licensee agrees to submit to the jurisdiction of California. 

    8.03.  Relationship of the Parties.  Nothing in this
Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee, or joint venture relationship between the Parties. 

    8.04.  Further Acts and Instruments.  Each Party hereto
agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate to effect the purpose and intent of this Agreement. 

    8.05.  Entire Agreement.  This Agreement constitutes and
contains the entire agreement of the Parties and supersedes any and all prior negotiations, correspondence, understandings and agreements between the Parties respecting the subject matter hereof. This
Agreement may be amended or modified or one or more provisions thereof waived only by a written instrument signed by the Parties. 

    8.06.  Severability.  If in any jurisdiction any one or
more of the provisions of this Agreement should for any reason be held by any court or authority having jurisdiction over this Agreement or any of the Parties hereto to be invalid, illegal or
unenforceable, such provision or provisions shall be validly reformed to as nearly approximate the intent of the Parties as possible and if unreformable, the Parties shall meet to discuss what steps
should be taken to remedy the situation; in other jurisdictions, this Agreement shall not be affected. 

    8.07.  Captions.  The captions to this Agreement are for
convenience only and are to be of no force or effect in construing and interpreting the provisions of this Agreement. 

    8.08.  WARRANTIES.  The Parties represent and warrant
that they have the power to enter into this agreement. OTHERWISE, THE PARTIES EXPRESSLY DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. 

    8.09.  Notices.  Any notice, request, approval or other
document required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given when delivered in person, transmitted by telex, telecopier,
telegraph or deposited in the mail, postage prepaid, for mailing by first class, certified or registered mail, return receipt requested, addressed as follows: 

If
to Licensee, addressed to:

Seattle Genetics, Inc.

22215 26th Ave. S.E. Suite 3000

Bothell, WA 98021

Attn: President 

7

If to Genentech, addressed to:

Genentech, Inc.

1 DNA Way

South San Francisco, CA 94080

Attn: Corporate Secretary 

or
to such other address or addresses as may be specified from time to time in a written notice. 

    8.10.  Wire Transfer of Funds.  Unless otherwise
specified in writing, all payments by Licensee required hereunder shall be made by wire transfer at the direction of Genentech. 

    IN
WITNESS WHEREOF, Genentech and Licensee have caused this Agreement to be executed by their duly authorized representatives. 

	 	 	SEATTLE GENETICS INC.
	 

 	 
 	 

By:	 
 	 

/s/ H. PERRY FELL   

	 

 	 
 	 

Title:	 
 	 
 President

	 

 	 
 	 

Date:	 
 	 

1-17-2000

	 

 	 
 	 
 GENENTECH INC.
	 

 	 
 	 

BY:	 
 	 

/S/ NICHOLAS J. SIMON   

	 

 	 
 	 

Title:	 
 	 
 Vice President

	 

 	 
 	 

Date:	 
 	 

24 January 2000

8

QuickLinks

Article I DEFINITIONS

Article II GRANT

Article III FEES AND ROYALTIES

Article IV RECORDS, REPORTS AND PAYMENTS

Article V LIABILITY

Article VI PATENT INFRINGEMENT

Article VII TERM AND TERMINATION

Article VIII MISCELLANEOUS PROVISIONS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]